Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Claudius, Rudin"'
Autor:
Oriana, Ciani, Martin, Hoyle, Toby, Pavey, Chris, Cooper, Ruth, Garside, Claudius, Rudin, Rod, Taylor
Publikováno v:
In Value in Health September-October 2013 16(6):1081-1090
Autor:
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Peter R.E. Johnson, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Nigel H. Russell, Graham H. Jackson, J. Anthony Child
Publikováno v:
Haematologica, Vol 97, Iss 3 (2012)
Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation.Design and Methods Oral cyclop
Externí odkaz:
https://doaj.org/article/041499dacc9f47dd98b2ea06bd51cabf
Autor:
Abdullah Pandor, Marrissa Martyn-St James, Jenny Byrne, Ruth Wong, Claudius Rudin, Mark Stevenson, John Stevens, Andrew Rawdin, Jean Hamilton
Publikováno v:
PharmacoEconomics. 36:903-915
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures ponatinib (Inclusig®; Incyte Corporation) to submit evidence for the clinical and cost effectivene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46cf30802fe669a89308110bee5e5786
https://doi.org/10.1007/s40273-018-0627-4
https://doi.org/10.1007/s40273-018-0627-4
Autor:
Chris Cooper, Tristan Snowsill, Irina A Tikhonova, Joanna Varley-Campbell, Ruben E. Mujica Mota, Claudius Rudin, Martin Hoyle
Publikováno v:
PharmacoEconomics. 35:363-373
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of azacitidine (Celgene) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of acute myeloid leukaemia with more than 30 % bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad1452f4cbb5c1fadf04f339e53e7b9
https://doi.org/10.1007/s40273-016-0453-5
https://doi.org/10.1007/s40273-016-0453-5
Autor:
Sue E. Bell, AJ Szubert, Kevin Boyd, Walter M Gregory, Sylvia Feyler, Claudius Rudin, Gareth J. Morgan, Roger G. Owen, Nuria Navarro Coy, Mark T. Drayson, Graham Jackson, Jennifer Byrne, A J Ashcroft, Faith E. Davies, Huw Roddie, J. Anthony Child, Gordon Cook, Fiona M. Ross, Wendy Osborne, Ping Wu
Publikováno v:
British Journal of Haematology. 166:109-117
Bisphosphonates are recommended in patients with osteolytic lesions secondary to multiple myeloma. We report on the safety of bisphosphonate therapy with long-term follow-up in the Medical Research Council Myeloma IX study. Patients with newly diagno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2200625e5bed0293faf8c0faaf6d79b8
https://doi.org/10.1111/bjh.12861
https://doi.org/10.1111/bjh.12861
Autor:
Fiona M. Ross, Graham Jackson, Sylvia Feyler, Mark T. Drayson, Kim Cocks, Walter M Gregory, Jennifer Byrne, Alex J Szubert, Gareth J. Morgan, Faith E. Davies, Sue E. Bell, J. Anthony Child, A John Ashcroft, Nuria Navarro-Coy, Gordon Cook, Huw Roddie, Claudius Rudin, Roger G. Owen
Publikováno v:
The Lancet. 376:1989-1999
Summary Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to establish whether bisphosphonat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde8a8d8d52eabbdd6e0e2790a0bc18a
https://doi.org/10.1016/s0140-6736(10)62051-x
https://doi.org/10.1016/s0140-6736(10)62051-x
Autor:
D Lawrence, Jennifer Treleaven, R. L. Powles, S Kulkarni, Gareth J. Morgan, C Horton, Bhawna Sirohi, A Leary, Claudius Rudin
Publikováno v:
Annals of Oncology. 18:1388-1394
Purpose: To compare the effects of pegylated interferon-alpha 2b (P-IFN) and interferon-alpha 2b (IFN) on quality of life (QoQ and toxicity in patients with multiple myeloma maintained on a steady dose of IFN. Patients and methods: Consenting, eligib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96e22efe2f3b92d29789c75c62be2937
https://doi.org/10.1093/annonc/mdm180
https://doi.org/10.1093/annonc/mdm180
Autor:
Samar Kulkarni, Seema Singhal, Jennifer Treleaven, Radovan Saso, Clive Horton, Ray Powles, Jayesh Mehta, Bhawna Sirohi, Claudius Rudin
Publikováno v:
Hematology. 10:361-364
Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft If standard infusional therapy (IC) has been used to treat myeloma at presentation, it is a matter of debate whether patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f493ce90b8cb25ed89411523fbcc8e4
https://doi.org/10.1080/10245330500234369
https://doi.org/10.1080/10245330500234369
Autor:
Jennifer Treleaven, Claudius Rudin, R. L. Powles, Samar Kulkarni, Jayesh Mehta, Radovan Saso, Bhawna Sirohi, Clive Horton, Seema Singhal
Publikováno v:
Bone Marrow Transplantation. 36:19-24
In all, 451 myeloma patients, 51% previously untreated, underwent elective single autotransplantation after 200 mg/m(2) melphalan between 1985 and 2001 at the Royal Marsden Hospital. The therapy sequence was: Induction (vincristine, doxorubicin, meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78205a68e160c5adbc43cae565827ad
https://doi.org/10.1038/sj.bmt.1705000
https://doi.org/10.1038/sj.bmt.1705000